Anixa Biosciences, Inc. (NASDAQ: ANIX), in partnership with Moffitt Cancer Center, announced the completion of dosing in the fourth cohort of its ongoing Phase 1 clinical trial evaluating FSHR-targeted CAR-T/CER-T therapy in recurrent ovarian cancer. The therapy has demonstrated a positive safety profile with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity (ICANS).
Science Significance
The study represents a first-in-human trial of FSHR-mediated CAR-T technology, which targets the follicle-stimulating hormone receptor (FSHR), a receptor selectively expressed on ovarian cells and tumor vasculature. Early findings are scientifically significant because several patients remain alive beyond disease-specific median survival benchmarks, including one patient from the first cohort who is alive 28 months post-treatment. These results suggest potential efficacy even at low dose levels.
Regulatory Significance
The trial is designed primarily to assess safety, maximum tolerated dose, and preliminary efficacy signals. With no DLTs observed at increasing dose levels — including a 30-fold escalation from cohort one to four — the program is advancing toward the fifth cohort, which is expected to test 1×10⁷ CAR-positive cells/kg. These findings strengthen the regulatory case for advancing ovarian cancer CAR-T therapy through the FDA pathway for novel immunotherapies.
Business Significance
Advertisement
Anixa’s CAR-T program represents a differentiated approach in the crowded cell therapy market, leveraging a unique chimeric endocrine receptor-T cell (CER-T) platform. The partnership with Moffitt Cancer Center and exclusive worldwide license from The Wistar Institute provides strategic advantages in intellectual property and commercialization. Success in this program could enhance Anixa’s clinical-stage oncology portfolio, attracting further collaborations and investor interest.
Patients’ Significance
Ovarian cancer remains one of the most lethal gynecologic malignancies, with limited treatment options in recurrent disease. The trial offers hope for women who have failed multiple prior therapies. The absence of severe toxicities combined with survival benefits beyond expected benchmarks provides a potentially safer and more effective immunotherapy option compared with existing standards of care.
Policy Significance
The trial underscores the growing importance of innovative immunotherapies in addressing high-mortality cancers. Positive safety and early efficacy outcomes may encourage policymakers and regulators to continue supporting accelerated pathways for novel cell therapies. Partnerships between biotech innovators, leading cancer centers, and academic institutions reflect a broader policy trend toward collaborative translational research models.
Transaction Highlights
Anixa Biosciences, in collaboration with Moffitt Cancer Center, has successfully completed dosing of the fourth cohort in its Phase 1 ovarian cancer CAR-T clinical trial. This latest cohort received an escalated dose of 3×10⁶ CAR-positive cells per kilogram—a nearly 30-fold increase compared to the first cohort. No dose-limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity have been observed to date, underscoring the strong safety profile of the therapy. Importantly, several patients continue to survive beyond disease-specific median expectations, with one patient from the first cohort still alive 28 months post-treatment. Following a 30-day safety review of the fourth cohort, dosing of the fifth cohort—at a planned level of approximately 1×10⁷ cells/kg—is expected to begin.
Source: Anixa Biosciences, Inc. Press Release
